Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Savolitinib Formulations in Healthy Chinese Males
NCT03860948Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Apr 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of savolitinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoints: Area Under the Curve, Maximum Observed Plasma Concentration and 3 more. Started Apr 2019; status: completed.
02
Drugs
savolitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03860948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03860948.